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OBJECTIVE — Toexaminecardiovasculardisease(CVD)mortalityriskinmenwithdiabetes
only, metabolic syndrome only, and concurrent metabolic syndrome and diabetes.
RESEARCH DESIGN AND METHODS — We examined CVD mortality risk by meta-
bolicsyndromeanddiabetesstatusinmenfromtheAerobicsCenterLongitudinalStudy(ACLS)
(meanSDage45.110.2years).Participantswerecategorizedashavingneitherdiabetesnor
metabolic syndrome (n  23,770), metabolic syndrome only (n  8,780), diabetes only (n 
532), or both (n  1,097). The duration of follow-up was 14.6  7.0 years with a total of
483,079 person-years of exposure and 1,085 CVD deaths.
RESULTS — Age-, examination year–, and smoking-adjusted CVD death rates (per 1,000
man-years) in men with neither metabolic syndrome nor diabetes, metabolic syndrome only,
diabetes only, and both were 1.9, 3.3, 5.5, and 6.5, respectively. CVD mortality was higher in
men with metabolic syndrome only (hazard ratio 1.8 [95% CI 1.5–2.0]), diabetes only (2.9
[2.1–4.0]), and both (3.4 [2.8–4.2]) compared with men with neither. The presence of meta-
bolicsyndromewasnotassociated(1.2[0.8–1.7])withhigherCVDmortalityriskinindividuals
with diabetes. In contrast, the presence of diabetes substantially increased (2.1 [1.7–2.6]) CVD
mortality risk in individuals with metabolic syndrome.
CONCLUSIONS — The presence of diabetes was associated with a threefold higher CVD
mortalityrisk,andmetabolicsyndromestatusdidnotmodifythisrisk.Ourﬁndingssupportthe
fact that physicians should be aggressive in using CVD risk–reducing therapies in all diabetic
patients regardless of metabolic syndrome status.
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A
pproximately7.8%oftheU.S.pop-
ulation has diabetes, and it is esti-
mated that the number of adults
withdiabeteswillincreaseto48.3million
by 2050 in the U.S. and to 300 million
worldwide in the year 2025, representing
a 122% rise compared with 1995 (1–3).
The public health importance is great,
consideringthatindividualswithdiabetes
have more than twice the risk for prema-
turedeath,heartdisease,andstrokecom-
pared with individuals without diabetes
(1). Although clinical deﬁnitions differ
slightly, metabolic syndrome is generally
characterized as a clustering of abnormal
levels of blood lipids (low HDL and high
triglycerides), impaired fasting glucose,
elevated blood pressure, and excess ab-
dominal obesity (4–7). Approximately
25% of Americans and 50% of those
aged 50 years meet the National Cho-
lesterolEducationProgram(NCEP)Adult
Treatment Panel (ATP) III deﬁnition of
metabolic syndrome (8). Similar to indi-
viduals with diabetes, individuals with
metabolic syndrome have an increased
risk for premature death, heart disease,
and stroke (9–12).
Metabolic syndrome and diabetes
share many common characteristics, so it
is not surprising that 65–85% of individ-
uals with diabetes also have metabolic
syndrome (13–15). However, relativity
few studies have examined the effect of
the combination of metabolic syndrome
and diabetes on cardiovascular disease
(CVD) risk (11,13,14). A cross-sectional
study using National Health and Nutri-
tion Examination Survey data reported
that the prevalence of coronary heart dis-
ease (CHD) among individuals with dia-
betes and without metabolic syndrome
was similar to that in those without dia-
betes or metabolic syndrome (7.5 vs.
8.7%, respectively) (14). However, indi-
viduals with concurrent diabetes and
metabolic syndrome had a substantially
greater prevalence (19.2%) compared
with these groups. This ﬁnding suggests
that in individuals with diabetes there is
anincreasedriskforCHDonlywhenmet-
abolicsyndromealsoispresent.Similarly,
in a prospective study Hunt et al. (16)
reported that within individuals with di-
abetes, those with metabolic syndrome
have an increased risk for CVD mortality,
whereasindividualswithdiabetesbutnot
metabolic syndrome do not. However,
thisstudywasrelativelysmall(n2,815)
with only 117 CVD deaths. Finally, the
UK Prospective Diabetes Study (UKPDS)
reported that in individuals with type 2
diabetes, the presence of metabolic syn-
drome (NCEP) increased the risk of CVD
events(17).However,itwasnotedfrom
a clinical perspective that the presence
of metabolic syndrome in individuals
with diabetes provided little informa-
tion for detecting who has an increased
risk of CVD.
Given the high prevalence of both
metabolic syndrome and diabetes, it is of
great clinical and public health impor-
tance that we develop a better under-
standing of the interactions of diabetes
and metabolic syndrome on the risk of
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vestigation is to examine the risk of CVD
mortality in individuals with metabolic
syndrome only, diabetes only, and con-
current metabolic syndrome and diabetes
in a large prospective study population.
RESEARCH DESIGN AND
METHODS— The Aerobics Center
Longitudinal Study (ACLS) is a prospec-
tive study composed of patients who re-
ceived preventive medical examinations
at the Cooper Clinic in Dallas, Texas. The
current analysis included 34,179 men
aged20to88yearswhocompletedaclin-
ical examination including ﬁtness testing
between 1979 and 2002. The mean  SD
duration of follow-up was 14.6  7.0
years(range1–25)withatotalof483,079
man-years of exposure. During this pe-
riod there were 2,110 deaths, of which
1,085 (51.4%) were from CVD. The
present study sample was limited to men
because of the small number of women
with metabolic syndrome or diabetes in
the ACLS cohort. There were 9,692
women available for inclusion in this
study, of which 252 (5 CVD deaths) had
diabetes and 702 (17 CVD deaths) had
metabolic syndrome. Participants were
predominantly (95%) non-Hispanic
white and well educated and from mid-
dle-to-upper socioeconomic strata. Par-
ticipants provided written informed
consent to participate in the examination
and follow-up study. The study protocol
was approved annually by the Cooper In-
stitute Institutional Review Board.
Clinical examination
The comprehensive health evaluation is
described in detail elsewhere (18,19). A
fasting antecubital venous blood sample
was obtained, and serum samples were
analyzed in a laboratory that participates
inandmeetsthequalitycontrolstandards
of the Centers for Disease Control and
Prevention Lipid Standardization Pro-
gram. Health histories and medication
use were obtained from a self-adminis-
teredquestionnaireandveriﬁedbyaphy-
sician during the examination. Based on
self-report, smoking was deﬁned as never
smoker, past smoker, and current
smoker. Diabetes cases were deﬁned as
men who reported taking insulin, had a
physician-diagnosed history of diabetes,
or had a fasting plasma glucose concen-
tration 126 mg/dl (7.0 mmol/l) at
baseline (20). The metabolic syndrome
was deﬁned according to the criteria es-
tablished by the NCEP ATP III but using
thenewdeﬁnitionofimpairedfastingglu-
cose from the American Diabetes Associ-
ation (ADA) (4,20). Metabolic syndrome
was diagnosed in participants who had
three or more of the following ﬁve risk
factors: high blood pressure (130
mmHg systolic or 85 mmHg diastolic),
central obesity (waist circumference
102 cm); high triglycerides (1.69
mmol/l); low HDL cholesterol (1.04
mmol/l); and high fasting plasma glucose
(5.6 mmol/l). Men with normal blood
pressure or fasting plasma glucose who
indicated a history of physician-
diagnosed hypertension (n  1,446) or
type 2 diabetes (n  428), respectively,
werealsocodedaspositiveforhighblood
pressure or high fasting plasma glucose,
which added an additional 1,874 men to
the metabolic syndrome category.
Mortality surveillance
We followed participants for mortality
from their baseline examination until the
date of death or until 31 December 2003
for survivors. The primary method of
mortality surveillance was the National
Death Index. The underlying cause of
death was determined from the National
Death Index report or by a nosologist’s
review of ofﬁcial death certiﬁcates ob-
tained from the department of vital
records in the decedent’s state of resi-
dence. CVD mortality was deﬁned if the
primarycauseofdeathorifanyoftheﬁve
underlying causes of death were listed as
CVD, using ICD-9 codes 390–459 or
ICD-10 codes I00–I99.
Statistical analyses
Participants were grouped into one of
four metabolic syndrome–diabetes cate-
gories: 1) free of metabolic syndrome and
diabetes, 2) having metabolic syndrome
only,3)havingdiabetesonly,or4)having
both metabolic syndrome and diabetes.
Descriptive statistics were used to sum-
marize baseline characteristics separately
byCVDmortalitystatusandbymetabolic
syndrome–diabetes categories. Continu-
ous variables were compared using Stu-
dent’s t tests, and categorical variables
were compared using 
2 tests. Kaplan-
Meierplotswereusedtocomparesurvival
curves, and Cox proportional hazards
models were used to estimate adjusted
hazard ratios (HRs), associated 95% CIs,
and CVD mortality rates (deaths/1,000
man-years of follow-up).
The proportional hazards assump-
tion was conﬁrmed by examining the
log cumulative survival plots for expo-
sure categories. P values are two-sided,
and P  0.05 was accepted as statisti-
cally signiﬁcant. All analyses were per-
formed using SAS (version 9.0; SAS
Institute, Cary, NC).
RESULTS— Mean  SD age of the
study participants was 45.1  10.2 years.
Individuals who died of CVD were older
and had less favorable cardiovascular risk
factor proﬁles at baseline than survivors
(Table 1). The baseline characteristics of
participants by metabolic syndrome–
diabetes category are described in Table
2. There were 23,770 men who had nei-
ther diabetes nor metabolic syndrome,
8,780 with metabolic syndrome only,
532 with diabetes only, and 1,097 with
both metabolic syndrome and diabetes.
Thus, 67% (1,097 of 1,629) of individu-
als with diabetes had concurrent meta-
bolic syndrome. Follow-up was 14.6 
7.0 years for men without diabetes or
metabolicsyndrome,13.46.8yearsfor
men with metabolic syndrome only,
9.77.4formenwithdiabetesonly,and
10.8  6.7 for men with both (P 
0.001).
Age-, examination year–, and smok-
ing-adjusted survival curves for CVD
mortality by metabolic syndrome–
diabetes category are depicted in Fig. 1.
Removingcurrentsmokersfromthedata-
set did not appreciably change the
Kaplan-Meier plots (ﬁgure not pre-
sented). Age-, examination year–, and
smoking-adjusted rates (top panel) and
relative risk (bottom panel) of CVD mor-
tality across metabolic syndrome–
diabetescategoriesarepresentedinFig.2.
The adjusted CVD death rates (per 1,000
man-years) in men with neither, meta-
bolic syndrome only, diabetes only, and
both were 1.9, 3.3, 5.5, and 6.5, respec-
tively. The HRs followed a similar pattern
because the adjusted risk of CVD mortal-
itywashigherinmenwithmetabolicsyn-
drome only (HR 1.8 [95% CI 1.5–2.0]),
diabetes only (2.9 [2.1–4.0]), and both
(3.4 [2.8–4.2]) compared with men with
neither. Further adjustment for history of
CVD had no substantive effect on any of
the risks across groups because the ad-
justedriskofCVDmortalitywas1.7(95%
CI 1.5–1.9), 3.1 (2.2–4.2), and 3.1 (2.5–
3.8) for individuals with metabolic syn-
drome only, diabetes only, and both,
respectively, compared with that for men
with neither. In addition, limiting the
sample to individuals not using insulin
had no effect on any of the HRs. Last, we
examined the risk for CVD death for men
Metabolic syndrome, diabetes, and CVD mortality
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those for men with diabetes only and ob-
served that men with diabetes had a sig-
niﬁcantly greater risk of CVD mortality
(1.7 [1.2–2.3]).
To further explore the CVD risk asso-
ciated with metabolic syndrome within
individuals with diabetes, we conducted
analysesinasubsetofparticipantslimited
Table 1—Descriptive characteristics of 34,179 men grouped by survival status, ACLS, 1970–1997
Survivors CVD mortality P
n 33,094 1,085
Years of follow-up 14.2  7.0 12.8  6.1 0.001
Age (years) 44.7  9.9 56.4  10.8 0.001
BMI (kg/m
2) 26.6  3.9 27.1  4.1 0.001
Systolic blood pressure (mmHg) 121.1  13.5 128.9  17.2 0.001
Diastolic blood pressure (mmHg) 81.2  9.6 84.2  10.7 0.001
Waist circumference (cm) 94.0  11.0 97.4  12.3 0.001
Cholesterol (mmol/l mg/dl) 5.4  1.1 208.6  41.3 5.7  1.1 221.4  41.2 0.001
HDL cholesterol (mmol/l mg/dl) 1.2  0.3 45.8  12.0 1.1  0.3 42.8  11.7 0.001
Triglycerides (mmol/l mg/dl) 1.6  1.1 137.9  98.9 1.9  1.4 166.1  121.3 0.001
Fasting glucose (mmol/l mg/dl) 5.6  0.9 100.5  17.0 6.2  2.0 111.3  36.7 0.001
Cigarette smoking (%)
Never 51.1 31.3
Past 32.0 44.2
Current 16.9 24.4
Personal history of CVD (%) 1.7 15.2 0.001
Family history of CVD (%) 4.3 0.1 0.001
Data are means  SD or %.
Table 2—Baseline characteristics of 34,179 men grouped by metabolic syndrome and diabetes status, ACLS, 1970–1997
Neither metabolic
syndrome nor diabetes Metabolic syndrome only Diabetes only
Both metabolic syndrome
and diabetes
n 23,770 8,780 532 1,097
Years of follow-up 14.6  7.0 13.4  6.8 9.7  7.4 10.8  6.7
CVD deaths 555 375 39 116
Crude CVD death rate
(per 1,000) 1.6 3.2 7.5 9.8
Age (years) 44.0  10.0 46.8  9.8 49.2  11.2 52.4  9.6
BMI (kg/m
2) 25.4  2.9 29.4  4.2 25.8  2.8 31.0  5.3
Systolic blood pressure
(mmHg) 118.7  12.6 127.2  13.7 121.4  13.4 131.7  15.7
Diastolic blood pressure
(mmHg) 79.3  8.9 86.2  9.6 79.9  8.4 86.5  9.8
Waist circumference (cm) 90.4  8.5 102.5  11.3 91.5  8.5 107.0  13.3
Cholesterol (mmol/l mg/
dl) 5.3  1.0 204.4  39.9 5.7  1.1 221.0  42.2 5.2  1.0 201.7  39.6 5.6  1.2 217.6  44.7
HDL cholesterol (mmol/l
mg/dl) 1.3  0.3 48.9  11.6 1.0  0.2 37.7  8.8 1.3  0.3 50.5  10.8 1.0  0.2 37.3  8.3
Triglycerides (mmol/l
mg/dl) 1.2  0.7 106.5  60.2 2.4  1.4 215.2  122.7 1.1  0.5 101.0  43.6 2.8  1.9 247.3  168.3
Fasting glucose (mmol/l
mg/dl) 5.4  0.5 96.6  8.3 5.8  0.5 103.8  8.6 7.4  2.8 132.6  50.5 8.6  3.0 154.9  54.1
Cigarette smoking (%)
Never 52.3 45.4 60.0 47.0
Past 31.7 34.2 25.0 35.4
Current 15.9 20.4 15.0 17.6
Personal history of CVD
(%) 1.5 3.1 2.8 6.7
Family history of CVD
(%) 3.4 4.2 22.4 11.3
Data are means  SD or %.
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diabetes (n  1,629; 155 CVD deaths),
theconcurrentpresenceofmetabolicsyn-
drome was not associated (1.2 [95% CI
0.8–1.7]) with higher risk of CVD mor-
tality compared with individuals who did
not have metabolic syndrome. In con-
trast, when we examined the risk associ-
ated with diabetes on CVD mortality in
individuals with metabolic syndrome
(n  9,877; 491 CVD deaths), we ob-
served that the presence of diabetes in-
creased (2.1 [1.7–2.6]) the risk of CVD
mortality compared with that for individ-
uals with no diabetes.
Because the prevalence of metabolic
syndrome increases dramatically after age
50 years and previous reports have fo-
cused on older populations, we repeated
the primary analysis in a subsample lim-
ited to participants aged 50 years at
baseline (n  10,901; 797 CVD deaths).
Compared with data from the entire co-
hort, the CVD mortality rate in this older
subsample more than doubled in each
metabolic syndrome–diabetes category,
yet the pattern of CVD mortality risk
across metabolic syndrome–diabetes cat-
egories was similar to that from the entire
cohort. Adjusted CVD death rates (per
1,000 man-years) in men aged 50 years
with neither, metabolic syndrome only,
diabetes only, and both were 4.8, 8.0,
12.9, and 14.8, respectively. Compared
with men with neither (n  6,602), indi-
viduals with metabolic syndrome only
(n3,385),diabetesonly(n242),and
both (n  672) had 1.7 (95% CI 1.4–
1.9), 2.7 (1.9–3.8), and 3.1 (2.4–3.9)
greater adjusted risk for CVD death,
respectively.
We opted to use the most recent ADA
deﬁnition of impaired fasting glucose
(5.6 mmol/l). However, most previous
studies used the original NCEP deﬁnition
of metabolic syndrome that deﬁnes im-
pairedfastingglucoseas6.1mmol/l.To
assure that the use of the more recent
ADA impaired fasting glucose cut point
did not inﬂuence our ﬁndings, we re-
peated all analyses with metabolic syn-
drome deﬁned using the original NCEP
deﬁnition. This change in metabolic syn-
drome deﬁnition produced no apprecia-
ble change in any of the ﬁndings. For
example, by using the original NCEP def-
inition of metabolic syndrome, the age-,
examination year–, and smoking-
adjusted risk of CVD mortality was 1.7
(95% CI 1.4–1.9) in men with metabolic
syndrome only, 2.8 (2.0–4.0) in men
with diabetes only, and 2.8 (2.2–3.5) in
men with both compared with that in
men with neither. In addition, when the
metabolic syndrome–only group was
limited to euglycemic individuals (fasting
glucose 100 mg/dl), age-, examination
year –, and smoking-adjusted CVD mor-
tality was 1.7 (1.5–2.0) in men with met-
abolic syndrome only, 2.7 (1.9–3.7) in
menwithdiabetesonly,and3.0(2.5–3.7)
in men with both compared with that in
men with neither.
CONCLUSIONS — The primary
ﬁnding of this study is that, compared
with individuals free from metabolic syn-
drome and diabetes, individuals with di-
abetesonlyhadapproximatelyathreefold
increasedriskforCVD-associatedmortal-
ity. Of particular interest is the ﬁnding
that the addition of metabolic syndrome
to diabetes did not signiﬁcantly modify
the CVD mortality risk even though met-
abolic syndrome alone was associated
witha1.5-foldincreaseinCVDmortality.
The results were similar when the study
sample was limited to individuals aged
50 years, the age-group in which the
presence of metabolic syndrome and dia-
betes is most common and reﬂect similar
increasesinCVDmortalityriskcompared
with that in individuals with neither
diabetes nor the metabolic syndrome
(10,12).
Data examining the interaction of di-
abetes and metabolic syndrome are lim-
ited, and these data are inconsistent with
respect to both results and quality. Tong
et al. (15) reported that the presence of
metabolic syndrome (NCEP ATP III) was
associated with increased risk (HR 2.1
[95%CI1.8–3.5])forCHDinnativeChi-
nesesubjectswithdiabetes.Ahighlycited
report by Alexander et al. (14), who used
cross-sectional NHANES data showed
that the prevalence of CHD was substan-
tially higher in individuals with concur-
rent diabetes and metabolic syndrome
compared with that in individuals with
diabetes (19.2 vs. 7.5%, respectively).
However,theauthorsnotedthatgiventhe
cross-sectional study design, the data
shouldbeconsideredhypothesisgenerat-
ing. Hunt et al.(15), using data from the
San Antonio Heart Study, showed greater
risk of CVD mortality in individuals with
both diabetes and metabolic syndrome
(NCEP ATP III), compared with those
with diabetes alone (16). However, the
results of this study must be interpreted
with caution given the limited number of
CVD deaths (n  117). Cull et al. (17)
reported that in type 2 diabetic subjects
from the UKPDS, concurrent NECP-
deﬁned metabolic syndrome increases
CVD risk by 33%. However, the au-
thors noted that the addition of metabolic
syndrome to diabetes had little positive
predictive value (18% for ATP III crite-
ria) and concluded that there is limited
clinical value to assessing metabolic syn-
drome in individuals with diabetes. The
Figure 1—Data from the combined cohort of 34,179 men with 1,085 CVD deaths. Curves rep-
resent age- and smoking-adjusted survival rates with individuals categorized by diabetes (DM)
and metabolic syndrome (MS) status: neither, MS only, DM only, or MS & DM.
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for more datasets examining the interac-
tion of diabetes and metabolic syndrome
on future CVD risk.
Our ﬁndings are consistent with the
joint ADA and European Association of
Study of Diabetes statement on the clini-
cal utility of metabolic syndrome, in that
we found that diagnosing metabolic syn-
drome in individuals with diabetes of-
fered no additional clinical insight into
future CVD risk and that physicians
should be aggressive in using recom-
mended CVD risk–reducing therapies in
all individuals with diabetes regardless of
metabolic syndrome status (21). These
include optimizing blood glucose, blood
pressure,andlipids;theuseofantiplatelet
agents as appropriate; and counseling on
diet,physicalactivity,andsmokingcessa-
tion (22).
Our current study has a number of
limitations that deserve mention. The
ACLScohortispredominantlymale,Cau-
casian, well educated, and middle-to-
upper class, limiting the generalizability
of the study results. Data on duration of
diabetes were not available, and this may
be an important factor to consider in ex-
aminingthediabetes-CVDmortalityasso-
ciation because it has been noted that
individuals who have had diabetes for a
long period may have more subclinical
diseases. Further, we lack detailed infor-
mation on medication use. Although we
used an updated deﬁnition of impaired
fasting glucose, duplicate analysis using
the older deﬁnition had no meaningful
effect on our ﬁndings (data not shown).
Strengths of this study include the large
sample size with high internal validity,
availableclinicaldataanddetailedmed-
ical histories, and a long follow-up
period.
In conclusion, in this large cohort of
Caucasian men, the presence of diabetes
was associated with an approximately
threefold higher risk for CVD mortality,
and metabolic syndrome status did not
modifythisrisk.Ourﬁndingssupportthe
hypothesis that in individuals with diabe-
tes,physiciansshouldbeaggressiveinus-
ing CVD risk–reducing therapies in all
patients regardless of metabolic syn-
drome status.
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